$APDN
APPLIED DNA SCIENCES INC

2024 Q3 Form 10-Q Financial Statement

#000141057824001226 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $797.5K
YoY Change -72.66%
Cost Of Revenue $552.3K
YoY Change -66.49%
Gross Profit $245.2K
YoY Change -80.68%
Gross Profit Margin 30.75%
Selling, General & Admin $2.679M
YoY Change -18.63%
% of Gross Profit 1092.39%
Research & Development $913.0K
YoY Change 9.2%
% of Gross Profit 372.31%
Depreciation & Amortization $134.1K
YoY Change -61.58%
% of Gross Profit 54.7%
Operating Expenses $3.592M
YoY Change -13.0%
Operating Profit -$3.347M
YoY Change 17.05%
Interest Expense $36.30K
YoY Change 35.55%
% of Operating Profit
Other Income/Expense, Net -$101.00
YoY Change -97.09%
Pretax Income $1.850M
YoY Change -159.39%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings $1.880M
YoY Change -160.64%
Net Earnings / Revenue 235.71%
Basic Earnings Per Share $0.47
Diluted Earnings Per Share $0.47
COMMON SHARES
Basic Shares Outstanding 10.30M 984.7K
Diluted Shares Outstanding 4.014M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.44M
YoY Change -2.92%
Cash & Equivalents $6.431M $10.44M
Short-Term Investments
Other Short-Term Assets $416.4K
YoY Change -20.66%
Inventory $438.6K $469.9K
Prepaid Expenses
Receivables $362.0K $513.9K
Other Receivables $0.00
Total Short-Term Assets $8.048M $11.84M
YoY Change -0.97% -3.25%
LONG-TERM ASSETS
Property, Plant & Equipment $553.2K $530.7K
YoY Change -34.0% -54.56%
Goodwill
YoY Change
Intangibles $2.699M $2.699M
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets $750.0K
YoY Change -26.88%
Total Long-Term Assets $4.741M $4.848M
YoY Change -14.18% 36.59%
TOTAL ASSETS
Total Short-Term Assets $8.048M $11.84M
Total Long-Term Assets $4.741M $4.848M
Total Assets $12.79M $16.69M
YoY Change -6.32% 5.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.166M $1.599M
YoY Change 8.73% 52.05%
Accrued Expenses $1.375M
YoY Change -12.05%
Deferred Revenue $58.79K $51.29K
YoY Change -23.09% -81.41%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.398M $3.026M
YoY Change -15.72% 4.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $745.9K
YoY Change -86.92%
Total Long-Term Liabilities $745.9K
YoY Change -86.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.398M $3.026M
Total Long-Term Liabilities $745.9K
Total Liabilities $3.821M $4.456M
YoY Change -56.48% -48.16%
SHAREHOLDERS EQUITY
Retained Earnings -$309.7M -$306.4M
YoY Change 2.39% 2.52%
Common Stock $318.8M $318.8M
YoY Change 3.71% 4.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.143M $12.39M
YoY Change
Total Liabilities & Shareholders Equity $12.79M $16.69M
YoY Change -6.32% 5.7%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $1.880M
YoY Change -160.64%
Depreciation, Depletion And Amortization $134.1K
YoY Change -61.58%
Cash From Operating Activities -$3.495M
YoY Change 155.23%
INVESTING ACTIVITIES
Capital Expenditures $21.85K
YoY Change -9.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$21.85K
YoY Change -86.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.81M
YoY Change
NET CHANGE
Cash From Operating Activities -3.495M
Cash From Investing Activities -21.85K
Cash From Financing Activities 10.81M
Net Change In Cash 7.293M
YoY Change -576.33%
FREE CASH FLOW
Cash From Operating Activities -$3.495M
Capital Expenditures $21.85K
Free Cash Flow -$3.516M
YoY Change 152.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0000744452
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Registrant Name
EntityRegistrantName
APPLIED DNA SCIENCES INC.
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
682926
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10299384
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2024Q2 apdn Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2024Q2 apdn Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2024Q2 apdn Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2024Q2 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36745
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-2262718
dei Entity Address Address Line1
EntityAddressAddressLine1
50 Health Sciences Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Stony Brook
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11790
dei City Area Code
CityAreaCode
631
dei Local Phone Number
LocalPhoneNumber
240-8800
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
APDN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10299385
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10442131
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7151800
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
75000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
75000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
513871
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
255502
CY2024Q2 us-gaap Inventory Net
InventoryNet
469871
CY2023Q3 us-gaap Inventory Net
InventoryNet
330027
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
416427
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
389241
CY2024Q2 us-gaap Assets Current
AssetsCurrent
11842300
CY2023Q3 us-gaap Assets Current
AssetsCurrent
8126570
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
530735
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
838270
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2698975
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2698975
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
868081
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1237762
CY2024Q2 us-gaap Assets
Assets
16690091
CY2023Q3 us-gaap Assets
Assets
13651577
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2440688
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270388
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
533679
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
498598
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
51285
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
76435
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3025652
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2845421
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
194000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
194000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
334402
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
739162
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
684115
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
684115
CY2024Q2 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
186000
CY2023Q3 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
4285000
CY2024Q2 us-gaap Liabilities
Liabilities
4455636
CY2023Q3 us-gaap Liabilities
Liabilities
8779165
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10299385
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
682926
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
10301
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
683
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
318757698
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
307397623
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-306376012
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302447147
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
12391987
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4951159
CY2024Q2 us-gaap Minority Interest
MinorityInterest
-157532
CY2023Q3 us-gaap Minority Interest
MinorityInterest
-78747
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12234455
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4872412
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16690091
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13651577
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
797519
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2917341
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2618313
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12587707
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
552287
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
1648023
us-gaap Cost Of Revenue
CostOfRevenue
1846333
us-gaap Cost Of Revenue
CostOfRevenue
7133271
CY2024Q2 us-gaap Gross Profit
GrossProfit
245232
CY2023Q2 us-gaap Gross Profit
GrossProfit
1269318
us-gaap Gross Profit
GrossProfit
771980
us-gaap Gross Profit
GrossProfit
5454436
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2678894
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3292304
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8763450
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9440734
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
913031
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
836123
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2762040
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2796171
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
3591925
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4128427
us-gaap Operating Expenses
OperatingExpenses
11525490
us-gaap Operating Expenses
OperatingExpenses
12236905
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3346693
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2859109
us-gaap Operating Income Loss
OperatingIncomeLoss
-10753510
us-gaap Operating Income Loss
OperatingIncomeLoss
-6782469
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
36295
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
26783
us-gaap Investment Income Interest
InvestmentIncomeInterest
84972
us-gaap Investment Income Interest
InvestmentIncomeInterest
34108
apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-633198
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5160000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
278400
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9564000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-334700
apdn Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
-394000
apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
1633767
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-101
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3469
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9060
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6396
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1849501
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3114195
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3774563
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6407265
CY2024Q2 us-gaap Profit Loss
ProfitLoss
1849501
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-3114195
us-gaap Profit Loss
ProfitLoss
-3774563
us-gaap Profit Loss
ProfitLoss
-6407265
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-30295
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-14429
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-78785
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-52470
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
1879796
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3099766
us-gaap Net Income Loss
NetIncomeLoss
-3695778
us-gaap Net Income Loss
NetIncomeLoss
-6354795
apdn Deemed Dividend Related To Warrant Modifications
DeemedDividendRelatedToWarrantModifications
233087
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1879796
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3099766
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3928865
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6354795
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.47
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.80
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.85
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4014261
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4014261
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
645426
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
645426
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1830882
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1830882
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
645426
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
645426
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12908939
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
93748
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-3844246
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9158441
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
258604
CY2023Q1 us-gaap Profit Loss
ProfitLoss
551176
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9968221
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
340042
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-3114195
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7194068
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4872412
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
340705
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
45566
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-1130281
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4128402
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18831
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
171004
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-4493783
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-175385
CY2024Q2 apdn Shares And Pre Funded Warrants Issued In Public Offering
SharesAndPreFundedWarrantsIssuedInPublicOffering
10525063
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30336
CY2024Q2 apdn Stock Issued During Period Value Upon Exercise Of Warrants
StockIssuedDuringPeriodValueUponExerciseOfWarrants
4940
CY2024Q2 us-gaap Profit Loss
ProfitLoss
1849501
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12234455
us-gaap Profit Loss
ProfitLoss
-3774563
us-gaap Profit Loss
ProfitLoss
-6407265
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
619440
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1032568
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
6083
apdn Write Off Of Property And Equipment
WriteOffOfPropertyAndEquipment
62000
apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
9564000
apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
334700
apdn Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
-394000
apdn Registered Direct Offering Costs
RegisteredDirectOfferingCosts
633198
apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
1633767
us-gaap Share Based Compensation
ShareBasedCompensation
542045
us-gaap Share Based Compensation
ShareBasedCompensation
692394
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-255853
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
258368
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2640694
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
139844
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-325822
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
27186
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-632149
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-495671
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1631965
apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
-25150
apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
-287672
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10462332
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3537911
apdn Capitalized Transaction Costs For Asset Purchase Transaction Investing Activities
CapitalizedTransactionCostsForAssetPurchaseTransactionInvestingActivities
137604
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36654
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
78535
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36654
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-171139
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
394
apdn Net Proceeds From Sale Of Common Stock And Pre Funded Warrants
NetProceedsFromSaleOfCommonStockAndPreFundedWarrants
13788923
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13789317
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3290331
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3709050
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7901800
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15215285
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11192131
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11506235
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
apdn Capitalized Transaction Costs Included In Accounts Payable
CapitalizedTransactionCostsIncludedInAccountsPayable
390721
apdn Deemed Dividend Warrant Modifications
DeemedDividendWarrantModifications
233087
apdn Transaction Costs For Asset Purchase Included In Accounts Payable
TransactionCostsForAssetPurchaseIncludedInAccountsPayable
138122
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1545916
apdn Property Plant And Equipment Acquired And Included In Accounts Payable
PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable
275251
apdn Number Of Primary Markets That Use Company S Technologies
NumberOfPrimaryMarketsThatUseCompanySTechnologies
3
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Profit Loss
ProfitLoss
-3774563
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10462332
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10442131
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates include revenue recognition, recoverability of long-lived assets, including the values assigned to intangible assets and property and equipment, fair value calculations for warrants, contingencies, and management’s anticipated liquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates. </p>
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
797519
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2917341
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2618313
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12587707
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
25150
CY2024Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
40035
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10442131
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7151800
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
750000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
750000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11192131
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7901800
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19857130
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
488860
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and cash equivalents with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. As of June 30, 2024, the Company had cash and cash equivalents of approximately $10.1 million in excess of the FDIC insurance limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company’s revenues earned from sale of products and services for the three and nine-month periods ended June 30, 2024 included an aggregate of 28% and 26% from one customer, respectively, within the MDx Testing Services segment and an aggregate of 27% and 18%, respectively from one customer within the Therapeutic DNA Production Services segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company’s revenues earned from sale of products and services for the three and nine-month periods ended June 30, 2023 included an aggregate of 71% and 81%, respectively, from two customers within the MDx Testing Services segment. Three customers accounted for 67% of the Company’s accounts receivable at June 30, 2024 and three customers accounted for 60% of the Company’s accounts receivable at September 30, 2023.</p>
CY2024Q2 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
10100000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q2 apdn Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
114909
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
212079
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
201278
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
19859
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
153684
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
98089
CY2024Q2 us-gaap Inventory Net
InventoryNet
469871
CY2023Q3 us-gaap Inventory Net
InventoryNet
330027
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1599129
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1072161
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
708552
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1138235
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
133007
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
59992
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2440688
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270388
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2024Q2 apdn Class Of Warrant Or Right Number Of Shares Called By Each Pre Funded Warrant
ClassOfWarrantOrRightNumberOfSharesCalledByEachPreFundedWarrant
1
CY2024Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
12.18
CY2024Q1 apdn Threshold Period For Filing Of Registration Statement On Form S3 From Date Of Purchase Agreements
ThresholdPeriodForFilingOfRegistrationStatementOnFormS3FromDateOfPurchaseAgreements
P45D
CY2024Q1 apdn Threshold Period To Use Commercially Reasonable Efforts To Cause Registration Statement To Become Effective From Closing Of Purchase Agreements
ThresholdPeriodToUseCommerciallyReasonableEffortsToCauseRegistrationStatementToBecomeEffectiveFromClosingOfPurchaseAgreements
P90D
apdn Registered Direct Offering Costs
RegisteredDirectOfferingCosts
633198
CY2024Q1 apdn Class Of Warrant Or Right Sale Price Per Share
ClassOfWarrantOrRightSalePricePerShare
12.18
CY2024Q1 apdn Number Of Warrants Held By Other Investors Not Participate In Offering
NumberOfWarrantsHeldByOtherInvestorsNotParticipateInOffering
2904
CY2024Q1 apdn Class Of Warrant Or Right Sale Price Per Share
ClassOfWarrantOrRightSalePricePerShare
12.18
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-175385
CY2023Q4 apdn Maximum Aggregate Offering Price For Sale Of Stock
MaximumAggregateOfferingPriceForSaleOfStock
6397939
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4501
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
64397
apdn Capitalized Transaction Costs For Asset Purchase Transaction Written Off
CapitalizedTransactionCostsForAssetPurchaseTransactionWrittenOff
217000
apdn Change In Deemed Dividend Related To Warrant Modification
ChangeInDeemedDividendRelatedToWarrantModification
77757
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
261030
CY2023Q3 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
72.00
apdn Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
28305629
apdn Weighted Average Price Per Share Warrant Granted
WeightedAveragePricePerShareWarrantGranted
1.64
apdn Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
8626796
apdn Weighted Average Price Per Share Warrant Exercised
WeightedAveragePricePerShareWarrantExercised
0.00
apdn Class Of Warrant Or Right Forfeitures And Expirations
ClassOfWarrantOrRightForfeituresAndExpirations
191720
apdn Weighted Average Price Per Share Warrant Cancelled Or Expired
WeightedAveragePricePerShareWarrantCancelledOrExpired
57.00
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19748143
CY2024Q2 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
2.78
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19748143
apdn Area Of Property Under Operating Lease
AreaOfPropertyUnderOperatingLease
30000
CY2023Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2023Q1 apdn Area Of Laboratory Space
AreaOfLaboratorySpace
2500
CY2017Q4 apdn Lease For Satellite Testing
LeaseForSatelliteTesting
1108
CY2017Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2017Q4 apdn Base Rent During Initial Lease Term
BaseRentDuringInitialLeaseTerm
6500
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
183658
us-gaap Operating Lease Expense
OperatingLeaseExpense
538666
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
797519
CY2024Q2 us-gaap Gross Profit
GrossProfit
245232
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2917341
CY2023Q2 us-gaap Gross Profit
GrossProfit
1269318
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2618313
us-gaap Gross Profit
GrossProfit
771980
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12587707
us-gaap Gross Profit
GrossProfit
5454436
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
36295
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
26783
CY2024Q2 apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
5160000
CY2023Q2 apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
-278400
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-101
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3469
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1849501
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3114195
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
84972
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
34108
apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
9564000
apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
334700
apdn Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
-394000
apdn Registered Direct Offering Costs
RegisteredDirectOfferingCosts
633198
apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
1633767
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9060
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6396
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3774563
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6407265
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
5346000
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
5160000
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
186000
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4285000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
5071000
apdn Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Warrant Modification Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantModificationGainLossIncludedInEarnings
394000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
9564000
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
186000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-001226-index-headers.html Edgar Link pending
0001410578-24-001226-index.html Edgar Link pending
0001410578-24-001226.txt Edgar Link pending
0001410578-24-001226-xbrl.zip Edgar Link pending
apdn-20240630.xsd Edgar Link pending
apdn-20240630x10q.htm Edgar Link pending
apdn-20240630xex31d1.htm Edgar Link pending
apdn-20240630xex31d2.htm Edgar Link pending
apdn-20240630xex32d1.htm Edgar Link pending
apdn-20240630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
apdn-20240630_cal.xml Edgar Link unprocessable
apdn-20240630_def.xml Edgar Link unprocessable
apdn-20240630_lab.xml Edgar Link unprocessable
apdn-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apdn-20240630x10q_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending